Anti-CD11a monoclonal antibody M17
Alternative Names: Monoclonal antibody M17/4.4; Monoclonal antibody M17/4.4.11.9; Monoclonal antibody M17/5.2Latest Information Update: 15 Jan 2008
At a glance
- Originator Unknown
- Developer Bristol-Myers Squibb; Merck & Co
- Class Monoclonal antibodies
- Mechanism of Action CD11a antigen antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Transplant rejection